FI982413A - Substituoidut tiatsolidiinidionijohdannaiset - Google Patents

Substituoidut tiatsolidiinidionijohdannaiset Download PDF

Info

Publication number
FI982413A
FI982413A FI982413A FI982413A FI982413A FI 982413 A FI982413 A FI 982413A FI 982413 A FI982413 A FI 982413A FI 982413 A FI982413 A FI 982413A FI 982413 A FI982413 A FI 982413A
Authority
FI
Finland
Prior art keywords
thiazolidinedione derivatives
substituted thiazolidinedione
substituted
derivatives
thiazolidinedione
Prior art date
Application number
FI982413A
Other languages
English (en)
Swedish (sv)
Other versions
FI982413A0 (fi
Inventor
Colin Ripley Pool
Robin Sherwood Roman
Malcolm David Brightwell
Alan William Tremper
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10721461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI982413(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of FI982413A0 publication Critical patent/FI982413A0/fi
Publication of FI982413A publication Critical patent/FI982413A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
FI982413A 1992-09-05 1998-11-06 Substituoidut tiatsolidiinidionijohdannaiset FI982413A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929218830A GB9218830D0 (en) 1992-09-05 1992-09-05 Novel compounds
PCT/GB1993/001853 WO1994005659A1 (en) 1992-09-05 1993-09-01 Substituted thiazolidinedione derivatives

Publications (2)

Publication Number Publication Date
FI982413A0 FI982413A0 (fi) 1998-11-06
FI982413A true FI982413A (fi) 1998-11-06

Family

ID=10721461

Family Applications (2)

Application Number Title Priority Date Filing Date
FI951004A FI106263B (fi) 1992-09-05 1995-03-03 Menetelmä terapeuttisesti käyttökelpoisen 5-[4-[2-(N-metyyli-N-(2-pyridyyli)amino)etoksi]bentsyyli]tiatsolidiini-2,4-dionin maleiinihapposuolan valmistamiseksi
FI982413A FI982413A (fi) 1992-09-05 1998-11-06 Substituoidut tiatsolidiinidionijohdannaiset

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI951004A FI106263B (fi) 1992-09-05 1995-03-03 Menetelmä terapeuttisesti käyttökelpoisen 5-[4-[2-(N-metyyli-N-(2-pyridyyli)amino)etoksi]bentsyyli]tiatsolidiini-2,4-dionin maleiinihapposuolan valmistamiseksi

Country Status (38)

Country Link
US (1) US5910592A (fi)
EP (2) EP0960883A1 (fi)
JP (5) JP2828777B2 (fi)
KR (3) KR100371297B1 (fi)
CN (4) CN1040323C (fi)
AP (1) AP513A (fi)
AT (1) ATE182147T1 (fi)
AU (1) AU674880B2 (fi)
BR (1) BR1100916A (fi)
CA (2) CA2143849C (fi)
CY (1) CY2138B1 (fi)
CZ (2) CZ287473B6 (fi)
DE (2) DE69325658T2 (fi)
DK (1) DK0658161T3 (fi)
ES (1) ES2133410T3 (fi)
FI (2) FI106263B (fi)
GB (1) GB9218830D0 (fi)
GR (1) GR3030794T3 (fi)
HK (1) HK1012363A1 (fi)
HU (2) HU0500355D0 (fi)
IL (1) IL106904A (fi)
LU (1) LU90712I2 (fi)
MA (1) MA22970A1 (fi)
MX (1) MX9305397A (fi)
MY (1) MY111190A (fi)
NL (1) NL300035I2 (fi)
NO (4) NO303016B1 (fi)
NZ (1) NZ255505A (fi)
PL (1) PL173725B1 (fi)
RU (3) RU2128179C1 (fi)
SA (1) SA93140245B1 (fi)
SG (2) SG83747A1 (fi)
SI (1) SI9300452B (fi)
SK (1) SK280777B6 (fi)
TW (1) TW385309B (fi)
UA (1) UA41901C2 (fi)
WO (1) WO1994005659A1 (fi)
ZA (1) ZA936509B (fi)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
BR9711098B1 (pt) * 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
WO1998057634A1 (en) * 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
UA67743C2 (uk) * 1997-06-18 2004-07-15 Смітклайн Бічам П.Л.С. Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9723295D0 (en) * 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
AU770817B2 (en) * 1997-12-16 2004-03-04 Smithkline Beecham Plc 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,dione,maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
AU774613B2 (en) * 1997-12-16 2004-07-01 Smithkline Beecham Plc Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
EP1516617A2 (en) * 1998-07-21 2005-03-23 SmithKline Beecham plc Use of a thiazolidinedione for reducing apoptosis of pancreatic beta cells
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
DZ2937A1 (fr) 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
AU768994B2 (en) 1998-11-12 2004-01-15 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
OA11873A (en) * 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
EP1173435B1 (en) * 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
TR200200438T2 (tr) * 1999-08-17 2002-05-21 Smithkline Beecham P.L.C. Tiazolidindion türevleri içeren farmasötik terkipler ve bu terkipleri hazırlama prosesi.
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0014006D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
YU1203A (sh) * 2000-06-16 2006-05-25 Smithkline Beecham P.L.C. Lečenje i prevencija stanja vezanih za insulinsku rezistenciju srca
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
GB0019224D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2005229687B2 (en) * 2000-08-04 2008-03-13 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
AU2005229688B2 (en) * 2000-08-04 2008-04-03 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021785D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel Pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
MXPA03002580A (es) * 2000-09-26 2003-10-15 Cord Janet I Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion.
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
EP1349855B1 (en) * 2000-12-22 2006-08-23 Smithkline Beecham Plc 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione mesylate salt
WO2002051823A1 (en) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
AU2002343050A1 (en) * 2001-11-21 2003-06-10 Smithkline Beecham P.L.C. 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
KR20040062965A (ko) * 2001-11-21 2004-07-09 스미스클라인비이참피이엘시이 로시글리타존 에디실레이트 및 항당뇨제로서의 그의 용도
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
WO2003050116A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003053962A1 (en) * 2001-12-20 2003-07-03 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004062667A1 (en) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005058813A2 (en) * 2003-12-17 2005-06-30 Ranbaxy Laboratories Limited Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
CZ296472B6 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
KR100749219B1 (ko) * 2006-03-15 2007-08-13 건일제약 주식회사 신규한 로지글리타존 옥살산염, 이의 제조방법, 및 이를포함하는 약제학적 조성물
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
US8604245B2 (en) 2007-06-04 2013-12-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
CN101167726B (zh) * 2007-10-16 2011-05-18 宁夏康亚药业有限公司 马来酸罗格列酮分散片及其制备方法
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
CN102532122B (zh) * 2010-12-29 2015-12-02 开封制药(集团)有限公司 酒石酸罗格列酮的制备方法
CN106061940A (zh) 2013-11-05 2016-10-26 本古里安大学内盖夫研究发展局 治疗糖尿病和由其引发的并发疾病的化合物
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
IT201800002630A1 (it) * 2018-02-13 2019-08-13 Giuliani Spa Composizione per la prevenzione e il trattamento dei disturbi della crescita dei capelli

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197297A (en) * 1976-11-17 1980-04-08 Smithkline Corporation 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines
US4405211A (en) * 1980-07-29 1983-09-20 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Liquid crystal compositions with pleochroic anthraquinone dyes
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5039687A (en) * 1985-12-04 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamine compounds having enhancing activity
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
SK280777B6 (sk) 2000-07-11
DE10199002I2 (de) 2001-12-13
NL300035I2 (nl) 2001-07-02
NZ255505A (en) 1997-08-22
DE69325658D1 (de) 1999-08-19
CN1063942C (zh) 2001-04-04
CA2273147A1 (en) 1994-03-17
CN1051312C (zh) 2000-04-12
US5910592A (en) 1999-06-08
CN1066939C (zh) 2001-06-13
MA22970A1 (fr) 1994-04-01
RU98117628A (ru) 2000-08-20
CA2143849C (en) 2000-04-25
IL106904A0 (en) 1993-12-28
HU0500355D0 (en) 2005-05-30
AP9300562A0 (en) 1993-10-31
AU4973093A (en) 1994-03-29
IL106904A (en) 1997-09-30
FI982413A0 (fi) 1998-11-06
SI9300452B (sl) 2003-02-28
SI9300452A (en) 1994-06-30
HK1012363A1 (en) 1999-07-30
NO974646L (no) 1995-03-03
NO2001005I2 (no) 2004-06-01
JPH08501095A (ja) 1996-02-06
FI106263B (fi) 2000-12-29
PL173725B1 (pl) 1998-04-30
ATE182147T1 (de) 1999-07-15
NO2001006I1 (no) 2001-04-30
NO305802B1 (no) 1999-07-26
MX9305397A (es) 1995-01-31
KR20030097596A (ko) 2003-12-31
HU224212B1 (hu) 2005-06-28
HU9500659D0 (en) 1995-04-28
PL307812A1 (en) 1995-06-26
CN1101911A (zh) 1995-04-26
NO303016B1 (no) 1998-05-18
NO950852D0 (no) 1995-03-03
AP513A (en) 1996-07-30
GR3030794T3 (en) 1999-11-30
SG48302A1 (en) 1998-04-17
JP2002047288A (ja) 2002-02-12
JP2004359676A (ja) 2004-12-24
FI951004A0 (fi) 1995-03-03
SK27795A3 (en) 1995-08-09
CN1040323C (zh) 1998-10-21
BR1100916A (pt) 2000-07-04
DK0658161T3 (da) 1999-11-29
ZA936509B (en) 1994-06-16
CZ287473B6 (en) 2000-12-13
HUT72639A (en) 1996-05-28
AU674880B2 (en) 1997-01-16
RU98117673A (ru) 2000-07-20
KR20080081099A (ko) 2008-09-05
CN1183413A (zh) 1998-06-03
KR100371297B1 (ko) 2003-05-09
CN1183275A (zh) 1998-06-03
UA41901C2 (uk) 2001-10-15
WO1994005659A1 (en) 1994-03-17
RU2128179C1 (ru) 1999-03-27
EP0658161B1 (en) 1999-07-14
CZ56595A3 (en) 1995-11-15
CY2138B1 (en) 2002-06-21
EP0658161A1 (en) 1995-06-21
CN1183276A (zh) 1998-06-03
DE69325658T2 (de) 1999-12-30
NO950852L (no) 1995-03-03
FI951004A (fi) 1995-03-03
NL300035I1 (nl) 2001-03-01
NO974646D0 (no) 1997-10-08
ES2133410T3 (es) 1999-09-16
CA2143849A1 (en) 1994-03-17
SA93140245B1 (ar) 2005-10-15
MY111190A (en) 1999-09-30
JP2828777B2 (ja) 1998-11-25
TW385309B (en) 2000-03-21
GB9218830D0 (en) 1992-10-21
SG83747A1 (en) 2001-10-16
JPH11147885A (ja) 1999-06-02
KR950702982A (ko) 1995-08-23
CZ290591B6 (cs) 2002-08-14
JP2008208142A (ja) 2008-09-11
EP0960883A1 (en) 1999-12-01
RU95108329A (ru) 1996-12-20
LU90712I2 (fr) 2001-03-12

Similar Documents

Publication Publication Date Title
DK0658161T3 (da) Substituerede thiazolidindionderivater
ATA75293A (de) Indolderivate
DK154192D0 (da) Heterocycliske forbindelser
DE69208877D1 (de) Chinuclidinderivate
NO922182D0 (no) Krystallinske oksatiolan-derivater
DE69119329D1 (de) Actinonin-Derivate
FI925523A0 (fi) Hydroxi- och alkoxipyridinderivat
DE69125099D1 (de) Indolderivate
DE69330497D1 (de) Chinazolin-derivate
FI925763A (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
NO932146D0 (no) Benzimidazolderivater
ATE144765T1 (de) Hiv-hemmende benzenacetamidderivate
DE59308714D1 (de) Cyclobutan-benzol-derivate
DE69130255D1 (de) Oxadolderivate
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
DK0472733T3 (da) Phenantrenderivater
NO952288D0 (no) Benzazepinon-derivater
FI925469A (fi) Tiazolylsubstituerade kinolylymetoxifenylaettiksyraderivat
DE69313890D1 (de) 5-Aminoflavon-Derivate
NO933170D0 (no) Heterocykliske forbindelser
MX9206710A (es) Derivados de piridinol
DE69211197D1 (de) 1-Hydroxyvitamin D-Derivate
NO930739D0 (no) Substituerte fenylkinazolinderivater
KR930702353A (ko) 2- 카르바페넴 유도체
DE59309038D1 (de) Chlorthiazolderivate